A simple test is now available in the Wichita, Kan., area that determines if the aspirin you are taking to prevent a heart attack or stroke is effective.

The AspirinWorks(R) Test (aspirinworks) is available to doctors across Kansas through AMS Laboratory. Edwin Harned, AMS Laboratory president and CEO, said he's excited to introduce a test that gives physicians a tool to identify patients who are not benefitting from their aspirin therapy.

"Any time we have the chance to offer a test that gives the physician and patient good information about the validity of a drug that they are taking, we think it's a great test," said Harned.

Aspirin, taken by millions of Americans every day to reduce the risk of heart attack and stroke, works by making blood platelets less sticky and thus less likely to form a blood clot. Major clinical studies have shown that as many as one in four patients are resistant to the beneficial anti-platelet effects of aspirin.

"Not everyone responds the same to the same dose of aspirin," said Gordon Ens, Clinical Affairs Director for Corgenix Medical Corp. (OTC Bulletin Board: CONX), Wichita resident and developer of the AspirinWorks Test. "So we came up with a simple, non-invasive test to measure aspirin effect in individuals taking aspirin to reduce the risk of a heart attack and stroke."

The AspirinWorks Test determines the effect of aspirin on platelets by measuring the level of the biomarker called thromboxane B2 (11dhTxB2). The higher the levels of thromboxane B2, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy, which may be as simple as adjusting the dose.

AspirinWorks is the only FDA-cleared test that measures urinary thromboxane B2 to accurately determine aspirin effect in apparently healthy individuals. Unlike other platelet tests, which require freshly drawn blood that must be evaluated within four hours, the AspirinWorks Test only requires a urine sample that can be obtained at the doctor's office or AMS Laboratory patient service centers.

The AspirinWorks Test is reimbursed by most insurance carriers, and covered under Medicare and Medicaid.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at corgenix.

Statements in this press release that are not strictly historical facts are "forward looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Corgenix Medical Corporation
corgenix